Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Blot

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Letters|November 29, 2011
Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targetsCaroline Gest, Pezhman Mirshahi, Hong Li, et al.
Critical Reviews in Oncology/Hematology|November 2, 2010
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trialEtienne G C Brain, Cécile Mertens, Véronique Girre, et al.
Nature Medicine|January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerPierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
The Lancet. Oncology|November 21, 2007
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trialHervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Gynecologic Oncology|November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trialClémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Lancet (London, England)|August 2, 2025
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trialEtienne Brain, Olivier Mir, Emmanuelle Bourbouloux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II studyJean Louis Lefebvre, Yoann Pointreau, Frederic Rolland, et al.
The Lancet. Healthy Longevity|March 3, 2024
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trialJoël Guigay, Cécile Ortholan, Damien Vansteene, et al.
The Lancet. Healthy Longevity|May 17, 2024
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trialJoël Guigay, Hervé Le Caer, François-Régis Ferrand, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Letters|November 29, 2011
Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targetsCaroline Gest, Pezhman Mirshahi, Hong Li, et al.
Critical Reviews in Oncology/Hematology|November 2, 2010
Impact of liposomal doxorubicin-based adjuvant chemotherapy on autonomy in women over 70 with hormone-receptor-negative breast carcinoma: A French Geriatric Oncology Group (GERICO) phase II multicentre trialEtienne G C Brain, Cécile Mertens, Véronique Girre, et al.
Nature Medicine|January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerPierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.
The Lancet. Oncology|November 21, 2007
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trialHervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Gynecologic Oncology|November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trialClémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Lancet (London, England)|August 2, 2025
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trialEtienne Brain, Olivier Mir, Emmanuelle Bourbouloux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2013
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II studyJean Louis Lefebvre, Yoann Pointreau, Frederic Rolland, et al.
The Lancet. Healthy Longevity|March 3, 2024
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trialJoël Guigay, Cécile Ortholan, Damien Vansteene, et al.
The Lancet. Healthy Longevity|May 17, 2024
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trialJoël Guigay, Hervé Le Caer, François-Régis Ferrand, et al.
Pageof 2